- Pharvaris (PHVS, Financial) to present clinical data on deucrictibant at major congresses in May-June 2025.
- The data includes long-term safety and efficacy from CHAPTER-1 and RAPIDe-2 studies.
- Presentations will cover biomarker data, quality of life improvements, and CHAPTER-3 Phase 3 trial design.
Pharvaris (PHVS), a late-stage biopharmaceutical company, has announced that it will present new clinical data on its oral drug candidate, deucrictibant, across three major medical conferences scheduled between May and June 2025. The data will focus on long-term safety and efficacy, biomarkers, and trial designs for the treatment of hereditary angioedema (HAE).
The company will present at the 14th C1-Inhibitor Deficiency and Angioedema Workshop in Budapest, the Eastern Allergy Conference in Palm Beach, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Glasgow. These presentations will include results from significant extension studies, CHAPTER-1 and RAPIDe-2, which demonstrate both prophylactic and on-demand treatment benefits for HAE patients.
Key topics such as the pharmacokinetics of the XR tablet formulation, improvements in health-related quality of life, and plans for the Phase 3 CHAPTER-3 trial will be highlighted. Investors and interested parties can access the presentation materials on the Pharvaris investor relations website during the respective events. Pharvaris aims to deliver injectable-like efficacy with the convenience of oral therapy, addressing the unmet medical needs in bradykinin-mediated diseases.
